Obesity drug (and other treatments) market recalibrated

Despite a December advisory panel recommending Orexigen's Contrave for approval, the FDA this month reversed itself and rejected the combination drug, citing the need for long term safety and efficacy data and adding yet another blow to the obesity drug market — at least in the U.S.  Quick to declare the obesity drug market dead as a result, some market analysts have minimized (or ignored) the untapped demand for an effective obesity drug, the non-U.S. obesity drug markets that are, indeed, influenced by the U.S. FDA, but nonetheless free to operate of their own accord and readily do, and the number of obesity drugs still in the pipeline in the U.S. (including, potentially, Contrave among them).

Nonetheless, since we provided a comprehensive analysis of the obesity drug and device market in December, in which we recognized the challenges that other obesity drugs (e.g., lorcaserin, sibutramine, etc.) had encountered, but had crossed our fingers on the potential FDA approval of Contrave, the drug's FDA-tarnished U.S. prospects prompted us to revised our forecast of the balance of the obesity market across the range of treatment options:

  • Satiety Drugs
  • Malabsorption Drugs
  • Appetite Suppression Drugs
  • Combination Drugs
  • Restrictive Devices
  • Artificial Fullness Devices
  • Mal-absorption Devices
  • Gastric Emptying Devices
  • Appetite Suppression Devices

The MedMarket Diligence Report #S835, "Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2011-2019", has been overhauled, with revised forecasts based on the recent market developments. The report is described in detail at this link and may be ordered online for immediate download or may be ordered via order form.